LUNGevity spoke with David Carbone, MD, PhD, who answered several questions about COVID-19 and lung cancer trials and infusion-related treatments from his perspective as a medical oncologist at The Ohio State University. It is important to note that the conversation took place on April 6, as issues around the COVID-19 pandemic can change rapidly.
The questions Dr. Carbone addressed fall into four categories:
- Clinical trials
- Infusion-related treatments (immunotherapy)
- Infusion-related treatments (chemotherapy)
- General message to the community